Arcturus Therapeutics believes it’s “highly unlikely” it will lose the promised government funding for its bird flu mRNA ...
Reports Q4 revenue $22.8M, consensus $44.64M. “We continue to progress our flagship rare disease programs and look forward to sharing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback